TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01173315

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin and mineral supplementation
Description: Group MV: Zinc sulfate and Magnesium oxide (providing 10 mg Zn and 125 mg Mg) and vitamin C (100 mg) and vitamin E (100 mg); Group MVB: both of the above mineral and vitamin supplements plus vitamin B1 (5 mg), vitamin B2 (5 mg), vitamin B6 (5 mg), biotin (50 µg), vitamin B12 (5 µg) and folic acid (0.5 mg); Group P: starch (placebo).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin and mineral supplementation
Description: Group MV: Zinc sulfate and Magnesium oxide (providing 10 mg Zn and 125 mg Mg) and vitamin C (100 mg) and vitamin E (100 mg); Group MVB: both of the above mineral and vitamin supplements plus vitamin B1 (5 mg), vitamin B2 (5 mg), vitamin B6 (5 mg), biotin (50 µg), vitamin B12 (5 µg) and folic acid (0.5 mg); Group P: starch (placebo).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vitamin and mineral supplementation
Description: Group MV: Zinc sulfate and Magnesium oxide (providing 10 mg Zn and 125 mg Mg) and vitamin C (100 mg) and vitamin E (100 mg); Group MVB: both of the above mineral and vitamin supplements plus vitamin B1 (5 mg), vitamin B2 (5 mg), vitamin B6 (5 mg), biotin (50 µg), vitamin B12 (5 µg) and folic acid (0.5 mg); Group P: starch (placebo).
Study: NCT01388855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Subjects receive cholecalciferol 20,000 IU daily for 30 days followed by 20,000 IU once weekly for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pills made to look like vitamin D but have no medication in them
Study: NCT00402792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone/Acetaminophen Extended-Release
Description: 1 tablet q 12 hours
Study: NCT05471284

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss
Description: The third factor tested framing of the response efficacy of participating in a cessation study by utilizing loss of not participating in a smoking cessation.
Study: NCT00402792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone/Acetaminophen Extended Release
Description: 2 tablets q 12 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets q 12 hours
Study: NCT01912950

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prowave LX IPL
Study: NCT00719160

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: esomeprazole
Description: 2 Interventions with esomeprazole 20 mg twice a day for 9 days vs. a placebo for 9 days while on a high protein diet
Study: NCT05471284

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss
Description: The third factor tested framing of the response efficacy of participating in a cessation study by utilizing loss of not participating in a smoking cessation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss
Description: The third factor tested framing of the response efficacy of participating in a cessation study by utilizing loss of not participating in a smoking cessation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gain
Description: The third factor tested framing of the response efficacy of participating in a cessation study by utilizing gain of participating in a smoking cessation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gain
Description: The third factor tested framing of the response efficacy of participating in a cessation study by utilizing gain of participating in a smoking cessation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gain
Description: The third factor tested framing of the response efficacy of participating in a cessation study by utilizing gain of participating in a smoking cessation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gain
Description: The third factor tested framing of the response efficacy of participating in a cessation study by utilizing gain of participating in a smoking cessation.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Does not include any of the three message factors.
Study: NCT00719160

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole
Description: 2 Interventions with esomeprazole 20 mg twice a day for 9 days vs. a placebo for 9 days while on a high protein diet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 20 mg twice a day for 9 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo 20 mg twice a day for 9 days
Study: NCT00971867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Solution, I.V., 100 mg/m2 Weekly for 6 of 7 weeks, Until disease progression or unacceptable toxicity became apparent
Study: NCT03207191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F16IL2
Description: F16IL2 dose escalation with provisional doses of 10, 20 and 30 Mio IU on Day 1, 8, 15 and 22 of each cycle through a rate-controlled intravenous infusion of 3 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836858
Description: BI 836858 dose escalation with provisional doses of 10, 20, 40, 80 and 160 mg on days 3, 10, 17 and 24 of each cycle through a rate-controlled intravenous infusion up to 5 hours
Study: NCT01519011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral azacitidine
Description: oral azacitidine 300-mg once daily for 3 total doses with two 150-mg tablets (fasted and fed) or three 100-mg tablets (fasted).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral azacitidine
Description: oral azacitidine 300-mg once daily for 3 total doses with two 150-mg tablets (fasted and fed) or three 100-mg tablets (fasted).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral azacitidine
Description: oral azacitidine 300-mg once daily for 3 total doses with two 150-mg tablets (fasted and fed) or three 100-mg tablets (fasted).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral azacitidine
Description: oral azacitidine 300-mg once daily for 3 total doses with two 150-mg tablets (fasted and fed) or three 100-mg tablets (fasted).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral azacitidine
Description: oral azacitidine 300-mg once daily for 3 total doses with two 150-mg tablets (fasted and fed) or three 100-mg tablets (fasted).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral azacitidine
Description: oral azacitidine 300-mg once daily for 3 total doses with two 150-mg tablets (fasted and fed) or three 100-mg tablets (fasted).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral azacitidine
Description: 300-mg (three 100-mg tablets) once daily for 21 days of a 28-day cycle.
Study: NCT00861666

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Forgiveness-Based Writing
Description: Participants will be asked to complete self-report measures during the initial session, will be given writing instructions and will complete the first writing task on-site. The first writing task will focus on describing an offense in which someone hurt or angered the participant, and about which the participant is still hurt and angry.~Eleven additional writing tasks will be completed at home, three per week for a month. Writing assignments will include topics such as describing thoughts and feelings about the offense, identifying possible motives or mitigating circumstances, identifying benefits of the offense itself, identifying times when one has offended others and how one felt afterwards, identifying benefits of letting go of the offense, and writing a letter to the offender.~Participants will return each written assignment to the study staff. All participants will be tracked closely by the study coordinator and receive a reminder phone call on the day of each writing task.
Study: NCT02530112

Intervention type: OTHER
Intervention: Survey

Intervention type: OTHER
Intervention: Survey

Intervention type: OTHER
Intervention: Survey
Study: NCT01793753

Intervention type: DRUG
Intervention: Propofol
Study: NCT04576728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimodulin
Description: IMP will be administered via IV infusion on 5 consecutive days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (human albumin 1%)
Description: IMP will be administered via IV infusion on 5 consecutive days.
Study: NCT04368507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YYB101
Description: 1. b (Dose level 0 cohort): YYB101 20mg/kg, Irinotecan 150 mg/m2 of each dose level, IV infusion on Day 1, Day15, and followed by every 2 weeks until disease progression or unacceptable toxicity~2. a Stage 1: YYB101 RP2D, Irinotecan 150 mg/m2 of each dose level, IV infusion on Day 1, Day15, and followed by every 2 weeks until disease progression or unacceptable toxicity
Study: NCT03629769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proxelan
Description: Administration of one suppository of proxelan once a day for 30 days
Study: NCT01704807

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: foot orthotics
Description: Experimental wore experimental orthotics throughout the study period as much of the day as possible.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham foot orthotic
Description: Control group wore sham insoles as much of the time as possible for the duration of the study period.
Study: NCT03832647

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Epiduo
Description: 100 per arm Adapalene/ Benzoyl Peroxide

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Epiduo
Description: 100 per arm Adapalene/ Benzoyl Peroxide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salicylic Acid
Description: Salicylic Acid

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hydréane légère
Description: moisturizer
Study: NCT01137513

Intervention type: DEVICE
Intervention: Observational Measurement of T-wave Alternans
Description: Measurement is similar to typical EKG

Intervention type: DEVICE
Intervention: T-wave Alternans
Description: T-Wave Alternans will be measured in an observational fashion
Study: NCT01062308

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Taping and Sham Taping
Description: Taping shoulder with Hospiplast tape.~Taping the shoulder after acute stroke to prevent shoulder injury and pain.~Taping the shoulder after acute stroke and compare with sham taping group.~Treatments:~1. Positioning technique~2. Handling technique~3. Range of motion exercises~4. Taping technique
Study: NCT03451019

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer Hydrochloride
Description: Single oral doses of lanthanum (1000 mg) or Sevelamer (2400 mg) were administered in random order 15 minutes after 5 g calcium carbonate with standardized meal
Study: NCT01062308

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Taping
Description: Shoulder Taping for 14 days which will be changed after every 3 days.
Study: NCT00251134

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zodin (drug)
Description: 1 gram omega-3-acid ethyl esters 90 daily for a period of 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil (placebo)
Description: 1 gram olive oil daily for a period of 12 months
Study: NCT00657423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treated by endostar combined with docetaxel and cisplatin
Description: recombinant human endostatin given intravenously,7.5mg/㎡,d1-14,2cycles. docetaxel given intravenously,75mg/㎡,d1,2cycles. cisplatin given intravenously,75mg/㎡,d1,2cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treated by docetaxel and cisplatin
Description: docetaxel given intravenously,75mg/㎡,d1,2cycles. cisplatin given intravenously,75mg/㎡,d1,2cycles.
Study: NCT01804088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Formula™ 535 Iliac Balloon-Expandable Stent
Description: Treatment of symptomatic vascular disease of the iliac arteries
Study: NCT03451019

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer Hydrochloride
Description: Single oral doses of lanthanum (1000 mg) or Sevelamer (2400 mg) were administered in random order 15 minutes after 5 g calcium carbonate with standardized meal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanthanum Carbonate
Description: Single oral doses of lanthanum (1000 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanthanum Carbonate
Description: Single oral doses of lanthanum (1000 mg)
Study: NCT05826873

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Discharge antibiotic stewardship intervention
Description: Hospitalists will be provided with group-level, quarterly feedback reports illustrating the number of prescriptions that had the appropriate antibiotic duration and appropriate antibiotic choice for each of the three conditions.
Study: NCT03488693

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: Radiotherapy given

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: Radiotherapy given
Study: NCT03113370

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Fish Oil capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Olive Oil
Study: NCT03488693

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Radiation
Description: No radiotherapy given
Study: NCT02728739

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transthoracic Echocardiogram (TTE) Assesment
Description: Transthoracic Echocardiogram (TTE) will be carried out on all heart failure patients with elevated BNP level (\>30 pg/ ml) for grading of MR severity within 7 days.
Study: NCT00461981

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIV, Trivalent Inactivated Influenza Virus Vaccine
Description: 0.25 mL will be administered intramuscularly for each of two doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluMist, Influenza Virus Vaccine Live
Description: 0.5 mL will be administered intranasally (approximately 0.25 mL into each nostril) for each of two doses
Study: NCT03526653

Intervention type: OTHER
Group type: OTHER
Intervention: exercise without visual stimuli
Description: exercise on an ergometer or motomed in an environment without other visual stimuli

Intervention type: OTHER
Group type: OTHER
Intervention: excercise with National Geografics
Description: exercise on an ergometer or motomed while watching the National Geografics channel on television

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise with MemoRide
Description: excercise on an ergometer or motomed with the interactive software program MemoRide with which participants can exercise in real life on a virtual manner
Study: NCT02993861

Intervention type: OTHER
Intervention: Anti-epileptics

Intervention type: OTHER
Intervention: Anti-epileptics

Intervention type: OTHER
Intervention: Anti-epileptics

Intervention type: OTHER
Intervention: Anti-epileptics
Study: NCT00448201

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peripheral blood stem cell transplantation
Description: Minimum total CD34+ cells of 3 x 10\^6 cells/kg and a maximum of 8 x 10\^6 cells/kg will be infused on Day 0

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peripheral blood stem cell transplantation
Description: Minimum total CD34+ cells of 3 x 10\^6 cells/kg and a maximum of 8 x 10\^6 cells/kg will be infused on Day 0
Study: NCT02391025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium-68 citrate
Description: Given via IV at time of imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Imaging procedure
Study: NCT00632567

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: caesarean section
Description: caesarean section for second delivery if the first had to be traumatic after forceps with anal sphincter rupture diagnosed with anal endosonography.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vaginal delivery
Description: vaginal delivery for second delivery if the first had to be traumatic after forceps with anal sphincter rupture diagnosed with anal endosonography.
Study: NCT02187549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HYMOVIS
Description: Intra-articular injection

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intra-Articular Injection
Study: NCT02370511

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Mitral Valve Replacement
Description: Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Mitral Valve Replacement
Description: Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Mitral Valve Replacement
Description: Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.
Study: NCT01817075

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate Skin Cleanser
Description: Given CHG cleansing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mild Soap Skin Cleanser
Description: Given control cleansing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02288104

Intervention type: DEVICE
Group type: OTHER
Intervention: needle based confocal endomicroscopy
Description: real time imaging of living tissue at microscopic scale, through a needle.
Study: NCT00970905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aprepitant
Description: aprepitant 125 mg po (Mondays), 80 mg po (Wednesdays), 80 mg po (Fridays) with doses scheduled 1-2 hours prior to the day's radiation fraction. Aprepitant will not be administered on weekend days. Aprepitant administration will continue until the last day of radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron 8 mg po bid, with the morning dose scheduled 1-2 hours prior to the day's radiation fraction. Ondansetron will not be administered on weekend days. Ondansetron administration will continue until the last day of radiotherapy.
Study: NCT03976752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genvoya
Description: Genvoya is a fixed-dose combination anti-retroviral drug containing tenofovir alafenamide (TAF), emtricitabine (FTC), elvitegravir (EVG), and cobicistat.~At the second study visit, participants will be provided with a single dose of Genvoya, and instructed to take the dose at home with documentation by digital, time-stamped photo or video. At the third study visit, which will occur 24 hours after home dosing, participants will be given another single dose of Genvoya at the clinic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genvoya
Description: Genvoya is a fixed-dose combination anti-retroviral drug containing tenofovir alafenamide (TAF), emtricitabine (FTC), elvitegravir (EVG), and cobicistat.~At the second study visit, participants will be provided with a single dose of Genvoya, and instructed to take the dose at home with documentation by digital, time-stamped photo or video. At the third study visit, which will occur 24 hours after home dosing, participants will be given another single dose of Genvoya at the clinic.
Study: NCT01221636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Solution for injection, Intravenous, 750 mg, 1 day

Intervention type: DRUG
Group type: OTHER
Intervention: Abatacept
Description: Solution for injection, Intravenous, 750 mg, 1 day
Study: NCT06337604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2092 capsules
Description: TNP-2092 capsules 300 mg twice daily(BID): Taken with 240 mL of warm water 30 minutes (± 5 minutes) after breakfast and dinner, with a 12-hour interval between the two doses. Such administration will last 14 consecutive days. The last administration will be on the morning of Day 15. There will be a total of 29 doses.
Study: NCT06337604

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TNP-2092 capsules placebo
Description: TNP-2092 Capsules Placebo 300 mg BID : Taken with 240 mL of warm water 30 minutes (± 5 minutes) after breakfast and dinner, with a 12-hour interval between the two doses. Such administration will last 14 consecutive days. The last administration will be on the morning of Day 15. There will be a total of 29 doses.
Study: NCT02405819

Intervention type: OTHER
Group type: OTHER
Intervention: 'My Care Plan'
Description: 'My Care Plan' is a patient-initiated survivorship care planning tool.

Intervention type: OTHER
Group type: OTHER
Intervention: 'Survivorship Care Plan Builder'
Description: 'Survivorship Care Plan Builder' is a provider-initiated survivorship care planning tool.
Study: NCT06337604

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rabeprazole sodium enteric-coated tablets
Description: Rabeprazole sodium enteric-coated tablets (20 mg BID): Taken with 240 mL of warm water 30 minutes (± 5 minutes) before breakfast and dinner for 14 consecutive days. The last administration will be on the morning of Day 15. There will be a total of 29 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium enteric-coated tablets
Description: Rabeprazole sodium enteric-coated tablets (20 mg BID): Taken with 240 mL of warm water 30 minutes (± 5 minutes) before breakfast and dinner for 14 consecutive days. The last administration will be on the morning of Day 15. There will be a total of 29 doses.
Study: NCT02876289

Intervention type: DRUG
Intervention: Perampanel